Village Farms International Inc (VFF) (Q3 2026) Earnings Call Highlights: Record Cannabis
Village Farms International reported Q3 2026 record cannabis revenues of $55M, with 43% from international markets. Adjusted EBITDA rose 18% to $18.2M, and net sales increased 5% sequentially. Gross margins declined due to softer trim market conditions. The company expects Delta 2 expansion to complete in Q1 2027, reaching 40 metric tons annually by mid-2027. It maintains a strong balance sheet with $80M cash and a $10M undrawn revolver.
How this was made

The 30-second read
Why it matters
The earnings beat on revenue and cash generation is positive, but margin declines and weaker domestic sales create a mixed outlook, likely leading to modest price volatility.
Market read
First‑report earnings for a small‑cap cannabis company; provides fresh data for sector investors.
What to watch
Strong cash position and upcoming Delta 2 capacity expansion may provide a longer‑term catalyst not reflected in the immediate price reaction.
Background
Village Farms International is a vertically integrated cannabis producer focusing on EU GMP‑certified product. The Q3 2026 call provides the first public disclosure of its quarterly results.
Ticker impact
Q3 2026 earnings call disclosed record cannabis revenue of $55M, 18% EBITDA growth, but margin compression and declining Canadian sales.
potential modest downside as investors digest lower margins and weaker Canadian trim sales
Revenue growth and positive cash balance are offset by declining gross margins and weaker domestic sales, leading to uncertain near-term price direction.
Market effects
Highlights growth in EU GMP‑compliant cannabis and international demand, signaling potential upside for other regulated cannabis producers.
European cannabis market may see increased investor interest due to Village Farms' expansion and export growth.
Adds data points to the broader cannabis sector, but limited impact on overall market indices.
Counterpoint
Margin compression and falling Canadian sales could signal deeper structural challenges, suggesting a short‑term pullback.
Key entities
- ExecutiveMichael DeGiglio
CEO who discussed growth strategy and EU GMP compliance.
- ExecutiveAnn Gillin Lefever
COO who addressed market share and facility details.

